secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001140361-24-030012
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire Pharma shareholders approve share increase to 125M, reject Lincoln Park issuance and officer exculpation
--------------------------------------------------------------------------------

- Shareholders approved amendment to increase authorized common stock from 75M to 125M, effective June 12.
- Shareholders rejected proposed issuance of shares to Lincoln Park Capital in excess of 19.99% of outstanding.
- Shareholders rejected charter amendment to exculpate officers.
- Board adopted amended bylaws with enhanced procedural rules for stockholder nominations and proposals.
- All seven director nominees elected; Ernst & Young ratified as auditor; say-on-pay advisory approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124030012/0001140361-24-030012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124030012/ef20031101_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-030012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer